知镜 Cognispect · 医学文献与研究工作台

Use of avacopan in granulomatosis with polyangiitis with predominant gastrointestinal and kidney involvement.

De Weerdt P, Janssens W, Mekeirele M, Balthazar T, Hermans K, Smeys C, Janssens P.
BMJ case reports · 2026-07-22 · PMID 42486653

文献摘要

Avacopan, an oral C5a receptor 1 antagonist, is approved as a glucocorticoid-sparing option for remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Since April 2026, its marketing authorisation is undergoing regulatory review by the US Food and Drug Administration and the European Medicines Agency. We report the case of a middle-aged man with granulomatosis with polyangiitis (GPA) presenting with severe gastrointestinal involvement complicated by recurrent bleeding and bowel perforations together with rapidly progressive glomerulonephritis. Despite rituximab and high-dose glucocorticoids, disease activity progressed. Avacopan was introduced as adjunctive therapy during critical illness. Its initiation was temporally associated with multi-organ recovery and enabled rapid corticosteroid withdrawal, with no evidence of hepatotoxicity. This case illustrates real-world use of avacopan in a severe multisystem GPA phenotype with gastrointestinal involvement and adds to the accumulating post-marketing clinical experience being evaluated in ongoing regulatory assessments of this agent.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。